Lobectomy versus segmentectomy in patients with stage T (> 2 cm and ≤ 3 cm) N0M0 non-small cell lung cancer: a propensity score matching study

Linlin Wang1†, Lihui Ge2†, Sibo You1, Yongyu Liu1 and Yi Ren1*

Abstract

Background: The safety and effectiveness of lung segmentectomy in patients with early non-small cell lung cancer (NSCLC) remains controversial. We have therefore reviewed the clinicopathologic characteristics and survival outcomes of patients treated with lobectomy or segmentectomy for early T (> 2 and ≤ 3 cm) N0M0 NSCLC.

Methods: We obtained data from the Surveillance, Epidemiology, and End Results database for patients who underwent lobectomy or segmentectomy between 2004 and 2015. To reduce bias and imbalances between the treatment groups, propensity score matching analysis was performed. We used Kaplan–Meier curves to estimate overall survival (OS) and lung cancer-specific survival (LCSS). We conducted univariate and multivariate Cox proportional hazards regression analyses to identify independent prognostic factors for OS and cancer-specific survival, and applied the Cox proportional hazards model to create forest plots.

Results: Before matching, both univariate and multivariate Cox regression analyses revealed that patients who underwent lobectomy exhibited better OS (P < 0.001) and LCSS (P = 0.001) than patients who underwent segmentectomy. However, after matching, survival differences between the groups were not significant; OS (P = 0.434) and LCSS (P = 0.593). Regression analyses revealed that age and tumor grade were independent predictors of OS and LCSS (P < 0.05).

Conclusions: Patients with stage T (> 2 and ≤ 3 cm) N0M0 NSCLC undergoing segmentectomy can obtain OS and LCSS similar to those obtained with lobectomy. Further studies are required considering the solid component effects and pathologic tumor types regarding segmentectomies. Additional long-term survival and outcome analyses should be conducted with larger cohorts.

Keywords: Forest plots, Non-small cell lung cancer (NSCLC), Propensity score matching (PSM), Surveillance, Epidemiology, and End Results (SEER) database, Survival analysis

Introduction

Lung cancer accounts for 11.6% of all cancers and 18.4% of cancer deaths. Malignant tumors are associated with the highest morbidity and mortality rates [1]. The most recent estimate predicts 228,820 new cases and 135,720 deaths in 2020, demonstrating the tremendous global impact of this disease, which has a 5-year survival rate
of approximately 19% [2]. Surgery is the preferred treatment for early-stage non-small cell lung cancer (NSCLC), and it is also the only proven method to cure lung cancer [3, 4]. The current National Comprehensive Cancer Network (NCCN) guidelines recommend lobectomy as the first-line treatment for early NSCLC. High-resolution computed tomography has increased the detection rate of early lung cancer. Compared with traditional lobectomy, segmentectomy fulfills the oncological requirements and also reduces some loss of lung function [5]. However, there is controversy regarding whether segmental resection is more appropriate than lobectomy for surgical treatment of early NSCLC [6]. This study aimed to evaluate the clinicopathologic characteristics and survival outcomes of patients with NSCLC after segmentectomy compared to those after lobectomy. We used a population-based national registry, the Surveillance, Epidemiology, and End Results (SEER) database, to analyze the clinical characteristics and prognoses of patients with T (≥ 2 and ≤ 3 cm) N0M0 NSCLC who received either segmentectomy or lobectomy. Based on the survival analysis results, we created forest plots using the Cox proportional hazards model.

Methods

Data collection

We extracted data from the SEER database (https://seer.cancer.gov/) using SEER*Stat software (v8.3.6, https://seer.cancer.gov/seerstat/) to identify patients with a confirmed diagnosis of NSCLC between 2004 and 2015 undergoing segmentectomy (SEER Surgery Code: 22) or lobectomy (SEER Surgery Codes: 30, 33). The inclusion criteria were: (1) diagnosis between 2004 and 2015; (2) tumor size (TS, maximum diameter on pathological assessment) > 2 cm, and ≤ 3 cm; (3) NSCLC diagnosis confirmed on histology; (4) one primary tumor; (5) survival for at least 1 month; (6) active follow-up; and (7) available clinical information. The exclusion criteria were: (1) incomplete survival or clinical data, including unknown race, tumor grade, marital status, SEER cause-specific death classifications, and vital status recodes; (2) previous history of surgery; (3) history of therapy (chemotherapy, radiotherapy and/or others); (4) diagnosis based solely on autopsy or death certificate (Fig. 1). The institutional review board of Shenyang Chest Hospital & Tenth People's Hospital approved the study. All methods were performed in accordance with the relevant guidelines and regulations.

Variables

This study utilized public data from the SEER database. The covariates included age, sex, race, marital status, laterality, primary site, histopathology, and tumor grade. We classified age into four groups: ≤ 60, 61–70, 71–80, and ≥ 81. Laterality was defined as left and right, with the primary site classified as upper, middle, and lower. The histopathology was defined as adenocarcinoma (ADC), squamous cell carcinoma (SCC), and other tumor types (others). The grade was classified as well- (I), moderately- (II), and poorly differentiated, or undifferentiated (III–IV), based on the eighth edition of the American Joint Committee on Cancer lung cancer staging system, and updated TS (≥ 2 and ≤ 3 cm) for all patients over all time periods. OS was defined as the time from operative day to death from any cause or lost to follow-up. LCSS was defined as the time from diagnosis to lung cancer, excluding other causes of death.

Propensity score matching

Propensity score matching (PSM) reduces the effects of bias and confounding variables, by removing confounding factors between groups, thereby increasing comparability between the groups [7]. We used PSM to control for inherent biases associated with cohort studies. Propensity scores were derived by logistic regression based on potentially confounding baseline characteristics of patients, including age, sex, race, marital status, laterality, primary site, histopathology, tumor grade, SEER cause-specific death classification and vital status recode. Subsequently, patients who underwent segmentectomy and lobectomy were paired, using the nearest neighbor matching method, a caliper width of 0.2, and no replacement, resulting in a 1:2 matched sample, reducing standardized differences to <0.1 after matching. Continuous and categorical variables were compared using the Student’s t test, chi-square test, and analysis of variance (ANOVA) after matching. This study employed Cox regression after PSM to identify more reliable causal inferences.

Statistical analysis

In this study, categorical variables are expressed as percentages, and continuous variables are expressed as means ± standard deviations (SDs). Variables were compared using the Student’s t test, chi-square test, and ANOVA. We used the Kaplan–Meier method to generate survival curves and analyzed differences between curves using the log-rank test. We used the Cox proportional hazards model to examine independent prognostic factors and calculate the hazard ratio [HR] and corresponding 95% confidence interval [CI]. Specific results are depicted as forest plots. Power Analysis and Sample Size (PASS) software was used for sample evaluation. Data were analyzed with Statistical Product and Service Solutions 26.0 software (SPSS, Inc., Chicago, IL, USA). P-values < 0.05 (two-sided) were considered statistically
significant. Survival curves and the forest plot were drawn with GraphPad Prism software (Version 8.3.1, GraphPad software Inc, California, USA).

Results
Patient and clinicopathologic characteristics
A total of 5783 patients who underwent segmentectomy or lobectomy between 2004 and 2015 were selected from the SEER database. Of these, 5531 (95.64%) received lobectomies, and 252 (4.36%) received segmentectomies. The patient characteristics are shown in Table 1. The two groups were similar regarding sex, race, marital status, primary tumor site, histopathology and tumor grade.

Survival analyses
Among the 5783 patients, the mean follow-up was 56.57 ± 38.31 (lobectomy: 56.97 ± 38.32, segmentectomy: 47.72 ± 37.03) months; \( P < 0.001 \). The median OS was 116 (95% CI 109.74–122.26) months for lobectomy vs. 68 (95% CI 56.39–79.61) months for segmentectomy. The 1-, 3-, 5-, and 10-year OS rates for all patients were 92.9, 80.4, 69.4, and 47.3%, respectively. For patients receiving lobectomies and those receiving segmentectomies the 1-, 3-, 5-, and 10-year OS rates were 92.9, 80.7, 69.6, and 48.0% and 90.8, 72.8, 55.2, and 30.7%, respectively. Both OS (HR 1.561; 95% CI 1.292–1.885; \( P < 0.001 \)) and LCSS (HR 1.551; 95% CI 1.198–2.009; \( P = 0.001 \)) were significantly worse for patients receiving segmentectomies compared with those receiving lobectomies (Fig. 2a, b).

We used univariate analyses to identify possible prognostic factors for lobectomy or segmentectomy for treating patients with NSCLC. We identified statistically significant (\( P < 0.05 \)) correlations between OS and LCSS with surgical procedure, age, sex, race, marital status, histopathology and grade (Table 2). Laterality and primary site were not significant prognostic factors in our univariate analyses (\( P > 0.05 \)). For OS, patients receiving lobectomies were significantly different compared with...
Table 1 Baseline patient characteristics before and after propensity score matching

| Characteristic               | Surgical procedure unmatching | Surgical procedure matching |
|-----------------------------|--------------------------------|-----------------------------|
|                            | Total (N = 5783)               | Lobectomy (N = 5531)        | Segmentectomy (N = 252) | Total (N = 755)   | Lobectomy (N = 503) | Segmentectomy (N = 252) | P value |
| Age (years), n (%)          | 0.001                          |                             |                           |                   |                   |                           | 0.472   |
| ≤ 60                        | 1351 (23.4)                     | 1308 (23.6)                 | 43 (17.1)                 | 129 (17.1)        | 86 (17.1)         | 43 (17.1)                 |         |
| 61–70                       | 2011 (34.8)                     | 1928 (34.9)                 | 83 (32.9)                 | 238 (31.5)        | 155 (30.8)        | 83 (32.9)                 |         |
| 71–80                       | 1945 (33.6)                     | 1855 (33.5)                 | 90 (35.7)                 | 295 (39.1)        | 205 (40.8)        | 90 (35.7)                 |         |
| ≥ 81                        | 476 (8.2)                       | 440 (8.0)                   | 36 (14.3)                 | 93 (12.3)         | 57 (11.3)         | 36 (14.3)                 |         |
| Mean ± SD                   | 67.47 ± 10.25                   | 67.37 ± 10.24               | 69.75 ± 10.32             | 69.67 ± 9.96      | 69.63 ± 9.78      | 69.75 ± 10.32            | 0.880   |
| Sex, n (%)                  | 0.743                          |                             |                           |                   |                   |                           |         |
| Female                      | 3225 (55.8)                     | 3087 (55.8)                 | 138 (54.8)                | 394 (52.2)        | 256 (50.9)        | 138 (54.8)                |         |
| Male                        | 2558 (44.2)                     | 2444 (44.2)                 | 114 (45.2)                | 361 (47.8)        | 247 (49.1)        | 114 (45.2)                |         |
| Race, n (%)                 | 0.605                          |                             |                           |                   |                   |                           | 0.944   |
| White                       | 4871 (84.2)                     | 4664 (84.3)                 | 207 (82.1)                | 625 (82.8)        | 418 (83.1)        | 207 (82.1)                |         |
| Black                       | 463 (8.0)                       | 439 (7.9)                   | 24 (9.5)                  | 70 (9.3)          | 46 (9.1)          | 24 (9.5)                  |         |
| Others                      | 449 (7.8)                       | 428 (7.7)                   | 21 (8.3)                  | 60 (7.9)          | 39 (7.8)          | 21 (8.3)                  |         |
| Marital status, n (%)       | 0.397                          |                             |                           |                   |                   |                           | 0.859   |
| Noa                         | 3430 (59.3)                     | 3237 (59.4)                 | 143 (56.7)                | 425 (56.3)        | 282 (56.1)        | 143 (56.7)                |         |
| Yes                         | 2353 (40.7)                     | 2244 (40.6)                 | 109 (43.3)                | 330 (43.7)        | 221 (43.9)        | 109 (43.3)                |         |
| Laterality, n (%)           | 0.005                          |                             |                           |                   |                   |                           | 0.817   |
| Left                        | 2418 (41.8)                     | 2291 (41.4)                 | 127 (50.4)                | 376 (49.8)        | 249 (49.5)        | 127 (50.4)                |         |
| Right                       | 3365 (58.2)                     | 3240 (58.6)                 | 125 (49.6)                | 379 (50.2)        | 254 (50.5)        | 125 (49.6)                |         |
| Primary Site, n (%)         | 0.063                          |                             |                           |                   |                   |                           | 0.659   |
| Upper                       | 3524 (60.9)                     | 3380 (61.6)                 | 144 (57.1)                | 428 (56.7)        | 284 (56.5)        | 144 (57.1)                |         |
| Middle                      | 305 (5.3)                       | 297 (5.4)                   | 8 (3.2)                   | 31 (4.1)          | 23 (4.6)          | 8 (3.2)                   |         |
| Lower                       | 1954 (33.8)                     | 1854 (33.5)                 | 100 (39.7)                | 296 (39.2)        | 196 (39.0)        | 100 (39.7)                |         |
| Histopathology, n (%)       | 0.111                          |                             |                           |                   |                   |                           | 0.290   |
| ADC                         | 2450 (42.4)                     | 2355 (42.6)                 | 95 (37.7)                 | 282 (37.4)        | 187 (37.2)        | 95 (37.7)                 |         |
| SCC                         | 1234 (21.3)                     | 1184 (21.4)                 | 50 (19.8)                 | 174 (23.0)        | 124 (24.7)        | 50 (19.8)                 |         |
| Others                      | 2099 (36.3)                     | 1992 (36.0)                 | 107 (42.5)                | 299 (39.6)        | 192 (38.2)        | 107 (42.5)                |         |
| Grade, n (%)                | 0.227                          |                             |                           |                   |                   |                           | 0.917   |
| 1                           | 1357 (23.5)                     | 1309 (23.7)                 | 48 (19.0)                 | 140 (18.5)        | 92 (18.3)         | 48 (19.0)                 |         |
| II                          | 2649 (45.8)                     | 2529 (45.7)                 | 120 (47.6)                | 356 (47.2)        | 236 (46.9)        | 120 (47.6)                |         |
| III–IV                      | 1777 (30.7)                     | 1693 (30.6)                 | 84 (33.4)                 | 259 (34.3)        | 175 (34.8)        | 84 (33.3)                 |         |
| OS, n (%)                   | 0.001                          |                             |                           |                   |                   |                           | 0.739   |
| Alive                       | 3754 (64.9)                     | 3616 (65.4)                 | 138 (54.8)                | 407 (53.9)        | 269 (53.5)        | 138 (54.8)                |         |
| Dead                        | 2029 (35.1)                     | 1915 (34.6)                 | 114 (45.2)                | 348 (46.1)        | 234 (46.5)        | 114 (45.2)                |         |
| LCSS, n (%)                 | 0.020                          |                             |                           |                   |                   |                           | 0.755   |
| Alive                       | 4706 (81.4)                     | 4515 (81.6)                 | 191 (75.8)                | 567 (75.1)        | 376 (74.8)        | 191 (75.8)                |         |
| Dead                        | 1077 (18.6)                     | 1016 (18.4)                 | 61 (24.2)                 | 188 (24.9)        | 127 (25.2)        | 61 (24.2)                 |         |

ADC: adenocarcinoma; SCC: squamous cell carcinoma; I, well differentiated; II, moderately differentiated; III–IV, poorly differentiated/ undifferentiated; OS, overall survival; LCSS, lung cancer-specific survival; SD, standard deviation

a No included separated, single (never married), divorced, unmarried or domestic partner and widowed
b P value between lobectomy and segmentectomy was calculated using the chi-square test
patients receiving segmentectomies ($P < 0.05$), regarding age > 60 years; sex; white, or other race; marital status; a right lateral; tumor location; ADC, or another tumor type; and grade I–III/IV tumors. For LCSS, the parameters showing significant differences between patients receiving lobectomies vs. segmentectomies ($P < 0.05$) were age ≥ 61 but ≤ 70 years and age ≥ 81 years; female sex; white, or other race; married; a right lateral or lower tumor location; ADC, and grade I tumors.

Multivariate analyses were performed using the Cox regression model and included surgical procedure, age, sex, race, marital status, histopathology result, and tumor grade. The results revealed that surgical procedure, age, sex, race, marital status, histopathology result, and tumor grade were independent predictors of OS and LCSS ($P < 0.05$) (Table 2).

**Propensity score matching survival analyses**

After 1:2 PSM, all data were complete, and all variables were well-balanced between the groups. The propensity scores before matching were 0.041 ± 0.047 for lobectomy and 0.099 ± 0.103 for segmentectomy ($P < 0.001$), whereas after matching, they were 0.053 ± 0.023 and 0.054 ± 0.023 for lobectomy and segmentectomy, respectively; $P = 0.855$. Finally, 755 patients (lobectomy: 503, segmentectomy: 252) were included in the study. There were no significant differences in baseline characteristics between the matched groups (Table 1). The mean duration of follow-up was 45.87 ± 34.64 (lobectomy; 44.95 ± 33.38, segmentectomy: 47.72 ± 37.03) months; $P = 0.300$. The median OS was 68 (95% CI 59.99–76.01) months for patients receiving lobectomies, vs. 68 (95% CI 56.39–79.61) months for patients receiving segmentectomies. For patients receiving lobectomies and those receiving segmentectomies the 1-, 3-, 5-, and 10-year OS rates were 88.2%, 70.5%, 54.1%, and 26.1%; and 90.8%, 72.8%, 55.2%, and 30.7%, respectively. However, the OS (HR 0.914, 95% CI 0.730–1.444; $P = 0.434$) and LCSS (HR 0.920; 95% CI 0.677–1.249; $P = 0.593$) were not significantly different between the lobectomy and segmentectomy groups after matching (Fig. 2c, d).

**Subgroup analyses of the matched groups**

Univariate analyses to identify possible prognostic factors after matching revealed statistically significant correlations between OS and LCSS for age, sex, histopathology, and tumor grade ($P < 0.05$). The multivariate analyses also revealed that age and tumor grade were independent predictors of OS and LCSS ($P < 0.05$) (Table 3). The subsequent multivariable Cox regression model showed that younger age and lower tumor grades were significant independent positive prognostic factors for OS. Older age and higher tumor grades (both $P < 0.05$) were significant independent negative prognostic factors for LCSS.
The forest plot of individual hazard ratios for overall survival and lung cancer-specific survival in patients with lobectomy vs. segmentectomy (Fig. 3).

**Discussion**

Surgery is the first-line treatment for NSCLC, and it is also the only method proven to cure lung cancer. Radical lobectomy resection remains the preferred treatment for early NSCLC. With the popularization of low-dose computed tomography for lung cancer screening, the detection rate for patients with early lung cancer has improved [8], and segmentectomy is being more widely used as a surgical treatment. Recent studies revealed that patients with NSCLC who underwent segmentectomies for lesions < 2 cm obtained similar oncolgic effects compared with those that received lobectomies [9–12]. Patients receiving segmentectomies also retained more lung function [13, 14]. The NCCN guidelines indicate that the standard recommendation for the treatment of early NSCLC patients is anatomic pulmonary resection. These guidelines further state that sublobar resection (i.e., segmentectomy or wedge resection) can be

| Characteristic | Univariate analysis (unmatching) | Multivariate analysis (unmatching) |
|---------------|---------------------------------|-----------------------------------|
|               | OS | LCSS | OS | LCSS | OS | LCSS |
|               | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value |
| Surgical procedure | | | | | | |
| Lobectomy | Reference | | | | | |
| Segmentectomy | 1.561 (1.292–1.885) | < 0.001 | 1.551 (1.198–2.009) | 0.001 | 1.447 (1.197–1.750) | < 0.001 |
| Age (years) | | | | | | |
| ≤ 60 | Reference | | | | | |
| 61–70 | 1.599 (1.390–1.838) | < 0.001 | 1.371 (1.147–1.638) | 0.001 | 1.484 (1.290–1.708) | < 0.001 |
| 71–80 | 2.314 (2.023–2.648) | < 0.001 | 1.780 (1.497–2.118) | < 0.001 | 2.189 (1.911–2.507) | < 0.001 |
| ≥ 81 | 3.870 (3.281–4.565) | < 0.001 | 2.469 (1.962–3.107) | < 0.001 | 3.674 (3.110–4.340) | < 0.001 |
| Sex | | | | | | |
| Female | Reference | | | | | |
| Male | 1.525 (1.398–1.664) | < 0.001 | 1.378 (1.223–1.553) | < 0.001 | 1.502 (1.370–1.647) | < 0.001 |
| Race | | | | | | |
| White | Reference | | | | | |
| Black | 1.619 (1.322–1.982) | < 0.001 | 1.373 (1.060–1.779) | 0.016 | 1.544 (1.260–1.892) | < 0.001 |
| Others | Reference | | | | | |
| Marital status | | | | | | |
| No | 0.790 (0.724–0.862) | < 0.001 | 0.087 (0.724–0.921) | 0.001 | 0.776 (0.708–0.851) | < 0.001 |
| Yes | Reference | | | | | |
| Laterality | | | | | | |
| Left | Reference | | | | | |
| Right | 1.011 (0.926–1.105) | 0.801 | 1.010 (0.895–1.140) | 0.873 |
| Primary site | | | | | | |
| Upper | 1.118 (1.017–1.229) | 0.020 | 1.159 (1.017–1.321) | 0.027 |
| Middle | 1.061 (0.860–1.308) | 0.582 | 1.126 (0.849–1.495) | 0.410 |
| Lower | Reference | | | | | |
| Histopathology | | | | | | |
| ADC | 1.356 (1.221–1.505) | < 0.001 | 1.425 (1.237–1.641) | < 0.001 | 1.203 (1.082–1.337) | 0.001 |
| SCC | 1.870 (1.667–2.097) | < 0.001 | 1.649 (1.402–1.939) | < 0.001 | 1.300 (1.152–1.467) | < 0.001 |
| Others | Reference | | | | | |
| Grade | | | | | | |
| I | Reference | | | | | |
| II | 2.065 (1.803–2.365) | < 0.001 | 2.370 (1.942–2.891) | < 0.001 | 1.745 (1.517–2.008) | < 0.001 |
| III–IV | 2.648 (2.307–3.040) | < 0.001 | 3.321 (2.718–4.057) | < 0.001 | 2.180 (1.887–2.520) | < 0.001 |

OS, overall survival; LCSS, lung cancer-specific survival; HR, hazard ratio; CI, confidence interval; ADC, adenocarcinoma; SCC, squamous cell carcinoma
appropriate in select patients with the following indications if technical conditions permit and do not increase the surgical risk: (1) Poor pulmonary reserve or another major comorbidity that contraindicates lobectomy; (2) Peripheral nodules $\leq 2$ cm with at least one of the following, pure ADC in situ (AIS) on histopathology, nodules with $\geq 50\%$ ground-glass appearance on CT scans, and radiologic surveillance confirming an extended doubling time ($\geq 400$ days) [15].

However, the more appropriate surgical treatment for patients with early-stage NSCLC remains debatable [16]. As a minimally invasive procedure, lobectomies do not retain as much normal lung tissue as possible under the premise of ensuring efficacy [17]. Segmentectomy involves more anatomic complexity and variation than lobectomy, and requires precise lesion positioning during surgery and the identification of lung boundaries [18–20]. Therefore technically, segmentectomy is a more difficult and demanding procedure than lobectomy. However, TS is an influencing factor for early NSCLC prognoses [21]. The results of an ongoing Randomized Controlled Trial (JCOG0802), have not reached

**Table 3** Univariate and multivariate analyses of OS and LCSS after propensity score matching

| Characteristic     | Univariate analysis (matching) | Multivariate analyses (matching) |
|--------------------|--------------------------------|----------------------------------|
|                    | OS (HR 95% CI) | P value | LCSS (HR 95% CI) | P value | OS (HR 95% CI) | P value | LCSS (HR 95% CI) | P value |
| Surgical procedure |LOBECTOMY Reference Reference | | | | | | | |
| Segmentectomy      | 0.914 (0.730–1.444) | 0.434 | 0.920 (0.677–1.249) | 0.593 | | | | |
| Age (years)        |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| $\leq 60$          | 2.231 (1.456–3.420) | $<0.001$ | 2.016 (1.152–3.527) | 0.014 | 2.012 (1.310–3.089) | 0.001 | 1.804 (1.028–3.164) | 0.040 |
| 61–70              | 3.530 (2.345–5.314) | $<0.001$ | 3.265 (1.918–5.558) | $<0.001$ | 3.169 (2.101–4.780) | $<0.001$ | 2.966 (1.738–5.062) | $<0.001$ |
| $\geq 81$          | 4.836 (3.073–7.610) | $<0.001$ | 3.119 (1.670–5.827) | $<0.001$ | 4.780 (3.030–7.540) | $<0.001$ | 3.078 (1.643–5.765) | $<0.001$ |
| Sex                |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| Male               | 1.419 (1.149–1.753) | 0.001 | 1.408 (1.056–1.876) | 0.020 | 1.212 (0.979–1.501) | 0.078 | 1.228 (0.918–1.642) | 0.166 |
| Race               |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| White              | 1.116 (0.730–1.705) | 0.613 | 1.074 (0.610–1.891) | 0.804 | | | | |
| Black              | 0.816 (0.460–1.445) | 0.485 | 0.854 (0.401–1.818) | 0.683 | | | | |
| Others             |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| Marital status     |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| No                 | 0.892 (0.722–1.102) | 0.288 | 1.064 (0.795–1.424) | 0.677 | | | | |
| Yes                |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| Laterality         |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| Left               | 1.117 (0.905–1.379) | 0.301 | 1.191 (0.894–1.587) | 0.231 | | | | |
| Right              |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| Primary site       |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| Upper              | 1.221 (0.978–1.525) | 0.077 | 1.189 (0.880–1.607) | 0.259 | | | | |
| Middle             | 1.076 (0.607–1.906) | 0.803 | 1.012 (0.464–2.204) | 0.976 | | | | |
| Lower              |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| Histopathology     |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| ADC                | 1.298 (1.012–1.663) | 0.040 | 1.589 (1.138–2.218) | 0.007 | 1.194 (0.927–1.537) | 0.169 | 1.456 (1.037–2.047) | 0.030 |
| SCC                | 1.619 (1.238–2.119) | <0.001 | 1.502 (1.021–2.209) | 0.039 | 1.248 (0.944–1.650) | 0.120 | 1.166 (0.781–1.740) | 0.453 |
| Others             |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| Grade              |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| I                  |Reference Reference Reference Reference Reference Reference Reference Reference | | | | | | | |
| II                 | 1.881 (1.325–2.670) | <0.001 | 1.612 (1.023–2.538) | 0.039 | 1.749 (1.216–2.516) | 0.003 | 1.430 (0.894–2.289) | 0.136 |
| III–IV             | 2.567 (1.803–3.653) | <0.001 | 2.218 (1.405–3.502) | 0.001 | 2.267 (1.370–3.274) | <0.001 | 1.957 (1.216–3.147) | 0.006 |

OS, overall survival; LCSS, lung cancer-specific survival; HR, hazard ratio; CI, confidence interval; ADC, adenocarcinoma; SCC, squamous cell carcinoma
a conclusion [22]. However, Dai et al. [23] reported that patients with NSCLC with tumors < 1 cm or between 1 and 2 cm receiving segmentectomies had worse OS and LCSS than patients receiving lobectomies. Veluswamy et al. [24] demonstrated that in patients with ADC tumors < 2 cm, the OS and LCSS after segmentectomy were similar to those of lobectomy. For SCCs, the OS and LCSS after segmentectomy were inferior to those of lobectomy. In our study, regarding the surgical procedure, we observed that before PSM, for OS and CSS, lobectomy achieved better outcomes than segmentectomy in early T (> 2 cm and ≤ 3 cm) N0N0 NSCLC lung cancer. However, similar to recent studies [25], after PSM, our results revealed no significant differences in patient survival between those receiving lobectomy vs. segmentectomy. Our research shows that for the T (> 2 cm and ≤ 3 cm) N0N0 stage, segmentectomy and lobectomy achieved the same clinical benefit and prognoses regarding OS and LCSS in patients with NSCLC. However, further studies are required focusing on the solid component effects and pathologic tumor types with respect to segmentectomies. In addition, age has been identified as a prognostic factor for OS and LCSS. With expanded cancer screening and the wide use of low-dose computed tomography, more patients are being diagnosed at an earlier age [26]. Recently, researchers suggested that postoperative complications are similar between the two procedures [27]. Therefore, whether segmentectomy can be safely and effectively applied in early NSCLC requires further research. This study provides a clinical basis for further investigation by the JCOG0802/WJOG4607L, JCOG1211, JCOG0804/WJOG4507L clinical trials [13, 28].

Compared with lobectomy, a major advantage of segmentectomy is the preservation of lung function. In theory, segmentectomy remove less lung tissue; however, preservation depends on the residual lung function after surgery. Therefore, the impact of the two procedures on lung function remains uncertain [29]. Harada et al. [30] reported that segmentectomy preserved more lung function than lobectomy, with segmentectomy exhibiting less lung function losses after surgery. Gu et al. [31] indicated that segmentectomies could help minimize forced vital capacity (FVC) loss, but not forced expiratory volume in 1 min (FEV1) or the diffusing capacity of the lung for carbon monoxide (DLCO). For a single lung segment resected after segmentectomy, the loss of lung function is twice that after lobectomy. However, for multiple primary lung cancer types, segmentectomy can potentially reduce the loss of lung function even further. Waller et al. [32] reported that for multiple primary lung cancer types, segmentectomy is recommended, and lung resection should be avoided; segmentectomy can also allow the performance of future lobectomies. Therefore, compared with lobectomy, segmentectomy could have more advantages for the retention of lung function over the short-term. The advantages of long-term lung function retention after segmentectomy requires further exploration. In the current study, we were unable to compare the differences in lung function concerning long-term survival.

![Fig. 3](https://example.com/fig3.png)

Fig. 3 Forest plot of individual hazard ratios for overall survival (a) and lung cancer-specific survival (b) in patients with lobectomy vs. segmentectomy. Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma.
after lobectomy vs. segmentectomy because of database limitations.

Limitations
As our data were collected from the SEER database, some biases and errors exist despite our PSM analysis. Limitations included (1) lack of detailed information regarding pre-, peri-, and postoperative patient details and outcomes; (2) none or unknown variables (such as tumor component) were grouped together, which could have led to data biases; (3) the 8th American Joint Committee on Cancer staging system was used, which possessed some inconsistencies in the data transformation process compared with earlier versions; and (4) the SEER database lacked information on imaging, smoking history, tumor markers, previous target therapy or immunotherapy, as well as several other parameters; therefore, our study could not address the impact of these factors on patient prognoses after segmentectomy or lobectomy, although they could have played significant roles.

Conclusions
Patients with stage T (≥2 cm and ≤3 cm) N0M0 NSCLC undergoing segmentectomy can obtain OS and LCSS similar to those undergoing lobectomy. Further studies focusing on the solid component effects and pathologic tumor types regarding segmentectomies are required. Additional long-term survival and outcome analyses should be conducted with larger cohorts to provide more robust data.

Abbreviations
NSCLC: Non-small cell lung cancer; SEER: Surveillance, Epidemiology, and End Results; CSS: Cancer-specific survival; CT: Computed tomography; PSM: Propensity score matching; OS: Overall survival; LCSS: Lung cancer-specific survival; SD: Standard deviations; HR: Hazard ratio; CI: Confidence interval; AJCC: American Joint Committee on Cancer; ADC: Adenocarcinoma; SCC: Squamous cell carcinoma; PASS: Power analysis and sample size; NCCN: National Comprehensive Cancer Network; RCT: Randomized Controlled Trial; LDCT: Low-dose computed tomography; FVC: Forced vital capacity; FEV1: Forced expiratory volume in 1 min; DLCO: Carbon monoxide lung diffusion capacity.

Acknowledgements
Not applicable.

Author contributions
LLW and LHG drafted the manuscript. The data acquisition was performed by LLW, LHG and SBY. YYL and YR designed the analysis. YR and LLW conceptualized and designed the study. All authors read and approved the final manuscript.

Funding
This study was supported by the Liaoning Province Science and Technology Program Project (2019H8/10300088). The funding agency played no role in the study design, data collection, analysis, or interpretation, and was not involved in writing the manuscript.

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Shenyang Chest Hospital and Tenth People’s Hospital. The SEER database was used with permission.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Thoracic Surgery, Shenyang Chest Hospital and Tenth People’s Hospital, No. 11, Beihai Street, Dadong District, Shenyang 110044, Liaoning, People’s Republic of China. 2Department of Health Management, Shengjing Hospital of China Medical University, No. 36, Sanhao Street, Heping District, Shenyang 110004, Liaoning, People’s Republic of China.

Received: 23 February 2022 Accepted: 29 April 2022

Published online: 11 May 2022

References
1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
3. Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32:973–82.
4. Wei S, Guo C, He J, Tan Q, Mei J, Yang Z, et al. Effect of vein-first vs artery-first surgical technique on circulating tumor cells and survival in patients with non-small cell lung cancer: a randomized clinical trial and registry-based propensity score matching analysis. JAMA Surg. 2019;154:e190972.
5. Caviezel C, von Rotz J, Schneiter D, Inci I, Hillinger S, Opitz I, et al. Improved postoperative lung function after sublobar resection of non-small-cell lung cancer combined with lung volume resection surgery in patients with advanced emphysema. J Thorac Dis. 2018;10:5270–10.
6. Hao B, Zhang L, Fan T, Liu B, Jiang W, Hu H, et al. Survival following segmentectomy or lobectomy in patients with stage IB non-small-cell lung cancer. Front Oncol. 2020;10:1066.
7. Baek S, Park SH, Won E, Park YR, Kim HJ. Propensity score matching: a conceptual review for radiology researchers. Korean J Radiol. 2015;16:286–96.
8. Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States–2010 to 2015. JAMA Oncol. 2017;3:1276–81.
9. Landreneau RJ, Normolle DP, Christie NA, Awais O, Wizorek JJ, Abbas G, et al. Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non small-cell lung cancer: a propensity-matched analysis. J Clin Oncol. 2014;32:2449–55.
10. Zeng W, Zhang W, Zhang J, You G, Mao Y, Xu J, et al. Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non-small-cell lung cancer. World J Surg Oncol. 2020;18:44.
11. Zhang L, Li M, Yin R, Zhang Q, Xu L. Comparison of the oncologic outcomes of anatomic segmentectomy and lobectomy for early-stage non-small-cell lung cancer. Ann Thorac Surg. 2015;99:728–37.
12. Ipseneldijk MA, Shoni M, Siegert C, Seegers J, van Engelenburg AKC, Tsai TC, et al. Oncological outcomes of lobar resection, segmentectomy and wedge resection for T1a non-small-cell lung carcinoma: a systematic review and meta-analysis. Semin Thorac Cardiovasc Surg. 2019;32:582–90.
13. Suzuki K, Saji H, Aokage K, Watanabe SI, Okada M, Mizusawa J, et al. Comparison of pulmonary segmentectomy and lobectomy: safety results of a randomized trial. J Thorac Cardiovasc Surg. 2019;158:895–907.
14. Bilgi Z, Swanson SJ. Current indications and outcomes for thoracoscopic segmentectomy for early stage lung cancer. J Thorac Dis. 2019;11:51662–9.
15. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN guidelines insights: non-small cell lung cancer, Version 2.2021. J Natl Compr Cancer Netw. 2021;19:254–66.
16. Landreneau RJ, Schuchert MJ. Is segmentectomy the future? J Thorac Dis. 2019;11:308–18.
17. Lin TH, Huang WL, Chang CC, Yen YT, Lai WW, Tseng YL, et al. Uniportal video-assisted thoracoscopic surgery lobectomy and segmentectomy for pulmonary sequestration. J Thorac Dis. 2018;10:3722–8.
18. Sato M, Kuwata T, Yamanashi K, Kitamura A, Misawa K, Imashimizu K, et al. Safety and reproducibility of virtual-assisted lung mapping: a multicentre study in Japan. Eur J Cardiothorac Surg. 2017;51:861–8.
19. Pischik VG, Kovalenko A. The role of indocyanine green fluorescence for intersegmental plane identification during video-assisted thoracoscopic surgery segmentectomies. J Thorac Dis. 2018;10:53704–11.
20. Quan YH, Oh CH, Jung D, Lim JY, Choi BH, Rho J, et al. Evaluation of intraoperative near-infrared fluorescence visualization of the lung tumor margin with indocyanine green inhalation. JAMA Surg. 2020;155:732–40.
21. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. 2005;129:87–93.
22. Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, et al. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010;40:271–4.
23. Dai C, Shen J, Ren Y, Zhong S, Zheng H, He J, et al. Choice of surgical procedure for patients with non-small-cell lung cancer ≤1 cm or > 1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol. 2016;34:34175–82.
24. Veluswamy RR, Ezer N, Mhango G, Goodman E, Bonomi M, Neugut AI, et al. Limited resection versus lobectomy for older patients with early-stage lung cancer: impact of histology. J Clin Oncol. 2015;33:3447–53.
25. Chan EG, Chan PG, Mazur SN, Normolle DP, Luketich JD, Landreneau RJ, et al. Outcomes with segmentectomy versus lobectomy in patients with clinical T1cN0M0 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021;161:1639–1648.e2.
26. Gu C, Wang R, Pan X, Huang Q, Zhang Y, Yang J, et al. Sublobar resection versus lobectomy in patients aged ≤35 years with stage IA non-small cell lung cancer: a SEER database analysis. J Cancer Res Clin Oncol. 2017;143:2375–82.
27. Bédart B, Abdelnour-Berchtold E, Perneger T, Licker MJ, Stefani A, Krull M, et al. Comparison of postoperative complications between segmentectomy and lobectomy by video-assisted thoracic surgery: a multicenter study. J Cardiothorac Surg. 2019;14:189.
28. Nakagawa K, Watanabe SI, Kunitch H, Asamura H. The Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group: past activities, current status and future direction. Jpn J Clin Oncol. 2017;47:194–9.
29. Charloux A, Quoix E. Lung segmentectomy: does it offer a real functional benefit over lobectomy? Eur Respir Rev. 2017;26:170079.
30. Harada H, Okada M, Sakamoto T, Matsuoka H, Tsubota N. Functional advantage after radical segmentectomy versus lobectomy for lung cancer. Ann Thorac Surg. 2005;80:2041–5.
31. Gu Z, Wang H, Mao T, Ji C, Xiang Y, Zhu Y, et al. Pulmonary function changes after different extent of pulmonary resection under video-assisted thoracic surgery. J Thorac Dis. 2018;10:2331–7.
32. Waller DA. Surgical management of lung cancer with multiple lesions: implication of the new recommendations of the 8th edition of the TNM classification for lung cancer. J Thorac Dis. 2018;10:52686–91.